Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
Rob M.A. de Bie, Carl E Clarke, Alberto J. Espay, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 5, pp. 452-461
Closed Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
Yuyan Tan, Peter Jenner, Shengdi Chen
Journal of Parkinson s Disease (2021) Vol. 12, Iss. 2, pp. 477-493
Open Access | Times Cited: 139
Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa
Roberto Cilia, Emanuele Cereda, Albert Akpalu, et al.
Brain (2020) Vol. 143, Iss. 8, pp. 2490-2501
Open Access | Times Cited: 122
Young Onset Parkinson’s Disease: A Modern and Tailored Approach
Bart Post, Lieneke van den Heuvel, Teije van Prooije, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. s1, pp. S29-S36
Open Access | Times Cited: 90
Non-invasive transcranial brain modulation for neurological disorders treatment: A narrative review
Ethar Ahmed Mosilhy, Eman E. Alshial, Mennatullah Mohamed Eltaras, et al.
Life Sciences (2022) Vol. 307, pp. 120869-120869
Closed Access | Times Cited: 55
Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies
Ali Abusrair, Walaa Elsekaily, Saeed Bohlega
Tremor and Other Hyperkinetic Movements (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 42
Metformin role in Parkinson’s disease: a double-sword effect
Mohammed Alrouji, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 4, pp. 975-991
Closed Access | Times Cited: 37
Neuroprotective effects of morroniside from Cornus officinalis sieb. Et zucc against Parkinson’s disease via inhibiting oxidative stress and ferroptosis
Li Mao, Junli Zhang, Lianyan Jiang, et al.
BMC Complementary Medicine and Therapies (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 31
Computer-Aided Drug Design towards New Psychotropic and Neurological Drugs
Georgia Dorahy, Zheng Chen, Thomas Balle
Molecules (2023) Vol. 28, Iss. 3, pp. 1324-1324
Open Access | Times Cited: 30
Alternating Magnetic Field-Promoted Nanoparticle Mixing: The On-Chip Immunocapture of Serum Neuronal Exosomes for Parkinson’s Disease Diagnostics
Mohamed Sharafeldin, Shijun Yan, Cheng Jiang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 20, pp. 7906-7913
Open Access | Times Cited: 24
The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson’s Disease: A Promising Therapeutic Approach
Y. So, Jae-Ung Lee, Ga-Seung Yang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1071-1071
Open Access | Times Cited: 10
Deep Brain Stimulation in Parkinson’s Disease
Andrés M. Lozano, Alfonso Fasano, Lennart Stieglitz
Cambridge University Press eBooks (2025), pp. 316-327
Closed Access | Times Cited: 1
Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review
Farzad Salehpour, Michael R. Hamblin
Biomolecules (2020) Vol. 10, Iss. 4, pp. 610-610
Open Access | Times Cited: 59
The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?
Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager, et al.
Journal of Parkinson s Disease (2020) Vol. 10, Iss. s1, pp. S65-S73
Open Access | Times Cited: 55
Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota
Xiaoting Zhou, Jiachen Lu, Kehong Wei, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 48
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
Stuart Isaacson, Robert A. Hauser, Rajesh Pahwa, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 9, pp. 100212-100212
Open Access | Times Cited: 18
Acupuncture for the Treatment of Neuropsychiatric Symptoms in Parkinson's Disease: A Systematic Review and Meta-Analysis
Anxin Zhang, Zefeng Song, Anqi Di, et al.
Complementary Therapies in Medicine (2024) Vol. 80, pp. 103020-103020
Open Access | Times Cited: 7
Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease
Joseph Seemiller, Christopher J. Morrow, Jared T. Hinkle, et al.
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 5, pp. 534-542
Closed Access | Times Cited: 7
Phosphorylation of AQP4 by LRRK2 R1441G impairs glymphatic clearance of IFNγ and aggravates dopaminergic neurodegeneration
Heng Huang, Lishan Lin, Tengteng Wu, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Transcranial photobiomodulation for brain diseases: review of animal and human studies including mechanisms and emerging trends
Hao Lin, Dongyu Li, Jingtan Zhu, et al.
Neurophotonics (2024) Vol. 11, Iss. 01
Open Access | Times Cited: 6
Parkinson's disease and skin
Nicki Niemann, Andrew Billnitzer, Joseph Jankovic
Parkinsonism & Related Disorders (2020) Vol. 82, pp. 61-76
Open Access | Times Cited: 42
Update on the diagnosis and management of Parkinson's disease
Christopher Kobylecki
Clinical Medicine (2020) Vol. 20, Iss. 4, pp. 393-398
Open Access | Times Cited: 40
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
Charles S. Venuto, Luoying Yang, Monica Javidnia, et al.
Annals of Clinical and Translational Neurology (2021) Vol. 8, Iss. 3, pp. 603-612
Open Access | Times Cited: 39
Ferroptosis as a New Mechanism in Parkinson’s Disease Therapy Using Traditional Chinese Medicine
Lijuan Wu, Meijun Liu, Jingtao Liang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 39
Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease?
Daniel Weiß, Jens Volkmann, Alfonso Fasano, et al.
Annals of Neurology (2021) Vol. 90, Iss. 5, pp. 699-710
Closed Access | Times Cited: 39
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease
Erwan Bézard, David Gray, Rouba Kozak, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 4, pp. 476-487
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top